Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (February 2019)

25 slides from Aerie Pharmaceuticals's investor presentation, Feb 12, 2019

  1. Slide 1: Company Overview Investor Presentation

    Slide 1: Company Overview Investor Presentation

    Exhibit 99.1 Company Overview Investor Presentation February 2019

  2. Slide 2: Important Information

    Slide 2: Important Information

    Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    Aerie Overview Aerie IOP–Reducing Products (IP 2030+) • Rhopressa® (netarsudil ophthalmic solution) 0.02% • Successful U.S. Launch in 2018 • Rocklatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% • PDUFA set for March 14, 2019 • GlobalizationPlan Under Way – Europe and Japan Pipeline A

  4. Slide 4: Rhopressa: Market Perspective

    Slide 4: Rhopressa: Market Perspective

    Rhopressa ®: Market Perspective Lumigan CAI 10% 8% 2017 U.S. Glaucoma Market Travatan 7% AA 10% - ~$3B Market, 37M TRx, 61M bottles Fixed Latanoprost - Half of volume first-line (PGAs) Combo 37% 15% - Half of volume 2-3X/Day Adjuncts BB 13% Rhopressa®: HCP’s Positioning as Concomitant Therapy - New

  5. Slide 5: Rhopressa Formulary Coverage Increasing

    Slide 5: Rhopressa Formulary Coverage Increasing

    Rhopressa ® Formulary Coverage Increasing As of 2/01/19: ~90% of Commercial Lives Covered ~40% Medicare Part D Lives Covered During Q1 2019 Expect Majority Preferred Tier 2 Coverage Commercial and Medicare Part D 35% 45% 55% 40% 40% 40% 10/01/18 2/01/19 10/01/18 2/01/19 ------------Commercial-------

  6. Slide 6: Rhopressa U.S. Launch Update

    Slide 6: Rhopressa U.S. Launch Update

    Rhopressa ® U.S. Launch Update Weekly IQVIA Rx’s, IQVIA Bottles and Sales-Out Bottles: Actual Sales-Out to Pharmacies as of 2/8/19 (week 44) YE 2018 Restated IQVIA data as of 2/1/19 (week 43) 10,000 9,356 Actual Sales-Out to Pharmacies 9,000 Restated IQVIA Bottles * 8,000 Restated IQVIA Rx's 6,705 7

  7. Slide 7: Rhopressa U.S. Launch Update

    Slide 7: Rhopressa U.S. Launch Update

    Rhopressa ® U.S. Launch Update Strong Net Sales and Volume Growth: Fully Expect to Meet $122 net sales $8.0 FY 2018 Net Sales per unit 70 $7.0 Guidance of $20 to $30 million 60 $6.0 50 $5.0 40 $4.0 $136 net sales 30 $3.0 per unit 20 $2.0 $1.0 10 $0.0 0 Q1 2018 Q2 2018 Q3 2018 Net Sales $ in millions

  8. Slide 8: Active Engagement at Key Conferences

    Slide 8: Active Engagement at Key Conferences

    Active Engagement at Key Conferences American Glaucoma Society Association of Research American Society of Cataract and (AGS) in Vision and Refractive Surgeons (ASCRS) March 2018 Ophthalmology (ARVO) April 2018 April 2018 European Glaucoma Society (EGS) Florence, May 2018 European Society of Catarac

  9. Slide 9: Rocklatan Combination Product Candidate

    Slide 9: Rocklatan Combination Product Candidate

    Rocklatan TM Combination Product Candidate TM Rocklatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Positioning as First Line Therapy: • Benefits of Rhopressa® while also targeting the secondary drain • Achieved statistical superiority to market-leading latanoprost - At each of nine ti

  10. Slide 10: Rocklatan Efficacy and Safety

    Slide 10: Rocklatan Efficacy and Safety

    Rocklatan TM Efficacy and Safety Efficacy: • RocklatanTM demonstrated statistical superiority over its components (market- leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points • Consistent incremental IOP-reduction over latanoprost and Rhopressa® in

  11. Slide 11: Rocklatan Phase 3 Month 12 Responder Analysis

    Slide 11: Rocklatan Phase 3 Month 12 Responder Analysis

    TM Rocklatan Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patientswith IOP Reduced to 18 mmHg or Lower 100% 82% 80% 72% 66% 60% 57% 60% 49%49% 43% 37%35% 40% 27% 26% 22% 20% 16% 12% 0% 14 mmHg 15 mmHg 16 mmHg 17 mmHg 18 mmHg Rhopressa® (n=148) Latanop

  12. Slide 12: Rocklatan Next Steps

    Slide 12: Rocklatan Next Steps

    Rocklatan™ Next Steps • March 14, 2019 PDUFA TM • Current U.S. sales force is now training for Rocklatan in advance of PDUFA • Medicare Part D formulary submission to payers expected in April 2019 • Commercial and Medicare Part D access expected to be accelerated in comparison to Rhopressa ® For Inv

  13. Slide 13: Expanding Aerie Franchise: Europe and Japan

    Slide 13: Expanding Aerie Franchise: Europe and Japan

    Expanding Aerie Franchise: Europe and Japan • Europe (2017 Europe “Big 5” Glaucoma Market: 91M units per year, 1.5X U.S. units) • MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, expect 12-month review • Mercury 3: 6-month safety and 90-day efficacy registration trial comparing TM Rocklatan

  14. Slide 14: Europe Glaucoma Market

    Slide 14: Europe Glaucoma Market

    Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) “Big 5” Europe Glaucoma Market – 2017 $1.0B; 91M TRx*, Market Share in TRx Non-PGA Market (47%) PGA Market (53%) Others Bimatoprost 2 - 4 Times Daily CAI Once Daily 2% Travoprost 10% 13% 5% AA 4% Latanoprost 19% 17% Non-

  15. Slide 15: Japan Glaucoma Market

    Slide 15: Japan Glaucoma Market

    Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) Japan Glaucoma Market – 2017 $0.8B; 54M TRx*, Market Share in TRx Non-PGA Market (48%) PGA Market (52%) ROCK Others Unoprostone Inhibitors Bimatoprost 2 - 4 Times Daily 2% Once Daily 4% Travoprost (Unoprostone is bid

  16. Slide 16: Advancing the Pipeline

    Slide 16: Advancing the Pipeline

    Advancing the Pipeline • Rhopressa® ResearchTargets • 24-hour IOP reduction • Potential in normal tension glaucoma (successful Pilot Phase 2 for Japan) • Aqueous humor dynamics (trabecular outflow, episcleral venous pressure) • Pseudoexfoliative glaucoma • Corneal healing • Sustained-Release Retina

  17. Slide 17: Retinal Eye Diseases – Aerie's Next Chapter

    Slide 17: Retinal Eye Diseases – Aerie's Next Chapter

    Retinal Eye Diseases – Aerie’s Next Chapter Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics • Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small m

  18. Slide 18: 2017 U.S. Retinal Disease Market

    Slide 18: 2017 U.S. Retinal Disease Market

    2017 U.S. Retinal Disease Market 2017 Sales: $5.3B Unit Sales: 6.8M others, steroids, others, steroids, 0.23 $0.15 $0.02 0.11 Lucentis, 0.86 Lucentis, $1.44 Eylea, 2.61 Eylea, $3.70 Avastin, $0.02 Avastin, 3.03 Sources: Mix of public information, IQVIA and estimates For Investor Use 18

  19. Slide 19: Aerie's Innovation in Retinal Disease

    Slide 19: Aerie's Innovation in Retinal Disease

    Aerie’s Innovation in Retinal Disease Small Molecule Drug Proprietary Drug Delivery Candidates Technology • DSM PEA Polymer • PLGA • Aerie Kinase Library • PRINT® Mfg • Non-Aerie drug candidates • Bio-erodible, sustained-release implant for intravitreal injection AMD DME RVO Dry AMD/GA Glaucoma Othe

  20. Slide 20: Retinal Eye Disease: Unmet Needs in AMD and DME

    Slide 20: Retinal Eye Disease: Unmet Needs in AMD and DME

    Retinal Eye Disease Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF • Complex pathology cannot be addressed by a single drug class Many patients do not achieve and/or maintain sufficient efficacy • AMD: Anti-VEGF efficacy often lost after 5–7 years of treatme

  21. Slide 21: Lead Retina Products

    Slide 21: Lead Retina Products

    Lead Retina Products AR-1105 (Dexamethasone) Implant • Indications: retinal vein occlusion (RVO) and DME • Target product profile vs. Ozurdex® • Longer duration of efficacy (6 mo vs 3 mo) • Improved administration due to smaller needle • Potential for fewer adverse effects due to lower peak drug lev

  22. Slide 22: Preclinical AR-13503 Provides Efficacy Similar to Eylea

    Slide 22: Preclinical AR-13503 Provides Efficacy Similar to Eylea

    Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Oxygen-induced retinopathy (OIR) mouse model - PDR Neovascular Area (+SEM) Vehicle 1.25 mg/kg AR-13503 1 mg/kg Eylea (n=14) (n=16) (n=14) Administration: Intraperitoneal QD Data on File For more in

  23. Slide 23: AR-13503 Synergistic to Eylea in Mouse Model

    Slide 23: AR-13503 Synergistic to Eylea in Mouse Model

    AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR Neovascular Area (+SEM) *** 35% 30% * * : p<0.01 *** : p<0.0001 25% -40% 20% -60% 15% 10% 5% 0% Vehicle Eylea (sub- AR-13503 (sub- Combination n=12 optimal dose) opt

  24. Slide 24: Evaluating Aerie's 3,500+ Owned Molecules

    Slide 24: Evaluating Aerie's 3,500+ Owned Molecules

    Evaluating Aerie’s 3,500+ Owned Molecules • Commencing screening for additional indications beyond ophthalmology • ROCK inhibition should have potential in: • Pulmonary health, including pulmonary fibrosis and bronchial asthma • Dermatology indications • Cancer Aerie molecules inhibit both ROCK1 and

  25. Slide 25: Summary

    Slide 25: Summary

    Summary • Key Priorities • Rhopressa®: Continued successful launch execution TM • Rocklatan : U.S. PDUFA set for March 14, 2019 • Globalization Strategy • Europe/Japan clinical path and commercialization strategy • Ireland Manufacturing Facility • Research Initiatives • Rhopressa® 24-hour IOP reduct

Source: SEC EDGAR · 8-K filed Feb 12, 2019

More decks from Aerie Pharmaceuticals Inc.